L19TNF
Sponsors
Philogen S.p.A.
Conditions
GlioblastomaGliomaGlioma of BrainLocally Advanced Basal Cell CarcinomaMelanoma Stage IIIMelanoma Stage IVSoft Tissue Sarcoma
Phase 1
Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
CompletedNCT03779230
Start: 2019-05-31End: 2023-06-27Updated: 2023-06-29
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
Active, not recruitingNCT04032964
Start: 2019-09-05End: 2024-12-31Updated: 2024-04-08
A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression
RecruitingNCT04573192
Start: 2021-02-19End: 2025-12-31Target: 142Updated: 2024-04-08
Phase 2
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
RecruitingNCT06284590
Start: 2024-07-12End: 2028-07-31Target: 162Updated: 2024-10-26
A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
RecruitingNCT06336291
Start: 2024-05-22End: 2026-06-30Target: 90Updated: 2025-01-24
A Study to Evaluate the Safety and Efficacy of L19TNF With Alkylating Chemotherapy for Patients With Recurrent IDH-mutant Astrocytoma or Oligodendroglioma
Not yet recruitingNCT07120984
Start: 2026-01-30End: 2029-01-30Target: 52Updated: 2025-08-13
L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Not yet recruitingNCT07227350
Start: 2026-02-01End: 2031-02-01Target: 180Updated: 2026-03-10